Novo Nordisk A/S $NVO Shares Bought by Capital International Investors

Capital International Investors grew its position in Novo Nordisk A/S (NYSE:NVO) by 52.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,713,424 shares of the company’s stock after acquiring an additional 6,092,192 shares during the period. Capital International Investors owned about 0.40% of Novo Nordisk A/S worth $982,969,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. True Wealth Design LLC lifted its holdings in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S in the third quarter worth $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S in the third quarter worth $30,000. Allianz SE lifted its holdings in Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after acquiring an additional 238 shares during the period. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $39,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo reached an agreement with Hims & Hers to sell branded Wegovy and Ozempic through Hims’ telehealth platform, and has dropped current court proceedings — removes a legal overhang and opens an additional direct-to-patient channel. Reuters: Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: The deal gives Novo access to Hims’ large digital footprint (reports cite ~2.5M subscribers), which could expand patient reach for obesity/GLP‑1 therapies without heavy incremental field sales. Seeking Alpha: Novo’s Quiet Comeback Begins
• Positive Sentiment: Novo confirmed a share repurchase programme (part of up to DKK 15bn over 12 months) — buybacks are supportive of EPS and signal capital-return focus. GlobeNewswire: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: CEO comments said the company is dropping current proceedings but reserved the right to resume if needed — that reduces immediate uncertainty while keeping legal options open. CNBC: Hims & Hers shares surge after Novo Nordisk ends legal feud
• Neutral Sentiment: Brokerages currently show a consensus around “Hold” and analysts have updated FY26 estimates — keep an eye on guidance/analyst revisions after the agreement and latest results. AmericanBankingNews: Novo Nordisk Given Consensus Recommendation of “Hold” AmericanBankingNews: Equities Analysts Offer Predictions for NVO FY2026 Earnings
• Negative Sentiment: Separately, analysts and markets remain concerned about competitive pressure (notably Lilly) and possible price concessions across the GLP‑1 franchise — recent commentary highlights large market‑cap erosion and the risk to margins. Zacks: NVO Stock Sheds Nearly $50B in Market Cap
• Negative Sentiment: Some institutional selling was reported (Cresset trimmed its NVO stake), a reminder that investor rotation and profit‑taking continue amid the sector reshuffle. DefenseWorld: Novo Nordisk Shares Sold by Cresset Asset Management

Analyst Ratings Changes

A number of research firms have recently weighed in on NVO. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Citigroup initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $53.93.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $39.77 on Tuesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market cap of $177.59 billion, a PE ratio of 11.46 and a beta of 0.74. The firm has a 50 day simple moving average of $51.18 and a 200-day simple moving average of $52.24. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.